Cargando…
Why Do We Still Need Large Scale Clinical Trial: The Case of n−3 PUFA
After the first reports about a protective effect on coronary heart disease (CHD) published more than 40 years ago, wide interest in the therapeutic use of n−3 polyunsaturated fatty acids (n−3 PUFA) aroused. Since then, many studies and meta-analyses have reported a significantly reduced risk of CHD...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Research Foundation
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385353/ https://www.ncbi.nlm.nih.gov/pubmed/22754534 http://dx.doi.org/10.3389/fphys.2012.00202 |